Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Paradigm Biopharmaceuticals Reports Negative Cash Flow of $4.85m for the March 2021 Quarter

08 Jun 2021  |  15:30:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Quarterly Update and Appendix 4C - quarterly

Paradigm Biopharmaceuticals reported negative cash flow of $4.85m for quarter ended 31 March 2021. Operating cash flow for the period was $(4.81m). Investing cash flow was $(11,000). Financing cash flow was $(31,000). Cash in hand at the end of the quarter was $81.1m. During the quarter, the Company was invited to present at the 39th J.P. Morgan Healthcare conference in January. The Company also advised that it made submission for its Pivotal study in subjects with pain associated with knee osteoarthritis with the submission of the Investigation New Drug (IND) application to the US Food and Drug Administration (FDA).

Consolidated Statement of Cash Flow for the Quarter ended 31 March 2021

Current Quarter $A'000- 31 March 2021 Year to Date $A'000-9 Months
Net Operating Cash Flows (4,811) (24,092)
Net Investing Cash Flows (11) (32)
Total Operating and Investing Cash Flows (4,822) (24,124)
Net Financing Cash Flows (31) 555
Net Increase (Decrease) in Cash Held (4,853) (23,569)
Cash at Beginning of Quarter/Year to Date 85,952 104,668
Cash at End of Quarter 81,099 81,099
Please click here for full details

See more ASX300 News Announcements